Promising combo for tough pancreatic cancer hits roadblock
NCT ID NCT04643405
First seen Jan 11, 2026 · Last updated May 22, 2026 · Updated 24 times
Summary
This study looked at adding an experimental drug, APG-1387, to standard chemotherapy for people with advanced pancreatic cancer that had stopped responding to treatment. The goal was to find the safest dose and see if the combination could shrink tumors or slow the disease. The study was stopped early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED PANCREATIC CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200032, China
Conditions
Explore the condition pages connected to this study.